| Trial ID: | L1032 |
| Source ID: | NCT00113958
|
| Associated Drug: |
Cinacalcet
|
| Title: |
Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Cinacalcet
|
| Outcome Measures: |
Primary: Secondary hyperparathyroidism in people with kidney failure. | Secondary: Uncontrolled secondary hyperparathyroidism
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2013-05-13
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00113958
|
